Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) Net Income towards Common Stockholders: 2021-2024

Historic Net Income towards Common Stockholders for Abivax (ABVX) over the last 4 years, with Dec 2024 value amounting to -$188.3 million.

  • Abivax's Net Income towards Common Stockholders fell 31.26% to -$54.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$151.6 million, marking a year-over-year decrease of 71.69%. This contributed to the annual value of -$188.3 million for FY2024, which is 18.48% down from last year.
  • Per Abivax's latest filing, its Net Income towards Common Stockholders stood at -$188.3 million for FY2024, which was down 18.48% from -$159.0 million recorded in FY2023.
  • Abivax's 5-year Net Income towards Common Stockholders high stood at -$50.2 million for FY2021, and its period low was -$188.3 million during FY2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$137.1 million, with a median of -$159.0 million in 2023.
  • Data for Abivax's Net Income towards Common Stockholders shows a maximum YoY slumped of 148.31% (in 2023) over the last 5 years.
  • Over the past 4 years, Abivax's Net Income towards Common Stockholders (Yearly) stood at -$50.2 million in 2021, then fell by 27.43% to -$64.0 million in 2022, then tumbled by 148.31% to -$159.0 million in 2023, then declined by 18.48% to -$188.3 million in 2024.